Literature DB >> 7538435

Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs.

C L DeVane1.   

Abstract

The pharmacokinetics and pharmacodynamics of chlorpromazine, haloperidol, clozapine, and risperidone are described. Most traditional antipsychotic drugs have similar pharmacokinetic profiles that differ from the newer agents in several key respects. Traditional agents tend to be completely absorbed and undergo extensive presystemic elimination, but clearance tends to be almost exclusively by hepatic-enzyme metabolism. The volume of distribution is large, steady-state plasma concentrations are highly variable, and many traditional antipsychotic drugs have pharmacologically active metabolites. The newer antipsychotic agents clozapine and risperidone are also well absorbed and undergo extensive presystemic elimination. They are cleared mostly through hepatic-enzyme metabolism, but a small portion of risperidone is cleared renally. Steady-state plasma concentrations of clozapine and risperidone exhibit large interpatient differences at therapeutic dosages. The primary metabolite of risperidone, 9-hydroxyrisperidone, has activity equipotent to that of the parent drug. It is not clear whether clozapine produces active metabolites. Basic information on the pharmacokinetics and pharmacodynamics of clozapine and risperidone is known; however, more information is needed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538435     DOI: 10.1093/ajhp/52.3_Suppl_1.S15

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  3 in total

1.  Use of complementary and alternative medicine in a large sample of anxiety patients.

Authors:  Alexander Bystritsky; Sarit Hovav; Cathy Sherbourne; Murray B Stein; Raphael D Rose; Laura Campbell-Sills; Daniela Golinelli; Greer Sullivan; Michelle G Craske; Peter P Roy-Byrne
Journal:  Psychosomatics       Date:  2012-02-01       Impact factor: 2.386

2.  The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.

Authors:  F Aweeka; D Jayesekara; M Horton; S Swan; L Lambrecht; K D Wilner; J Sherwood; R J Anziano; T A Smolarek; R Z Turncliff
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

3.  Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses.

Authors:  Josephine F Reyes; Sheldon H Preskorn; Ahsan Khan; Dinesh Kumar; Edward I Cullen; Carlos A Perdomo; Raymond D Pratt
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.